Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets with a focus on timely delivery and compliance with international standards.

Mirtazapine acts on central neurotransmitter pathways and is approved for several depressive conditions.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Bipolar depressive episodes: used as an adjunct to mood stabilizers to treat depressive phases of bipolar disorder. - Depression with insomnia: helps alleviate depressive symptoms while improving sleep quality.

Mirtazapine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hyponatremia, especially in elderly patients

When prescribing Mirtazapin Hexal, clinicians should consider several safety precautions.

- Monitor weight: patients may experience increased appetite and weight gain. - Check blood pressure: orthostatic hypotension can occur, especially at treatment initiation. - Assess for suicidal thoughts: heightened risk during early therapy. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: tapering reduces withdrawal symptoms. - Store at ambient temperature: keep in original container, protect from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crisis; a washout period is required. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce mirtazapine concentrations.